Finoriq research workspace
ANAPTYSBIO, INC (ANAB) Institutional Holdings & 13F Ownership
Track institutional investor activity, 13F holders, portfolio weights, and reported position changes for ANAPTYSBIO, INC (ANAB).
Company Snapshot
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
- Company
- ANAPTYSBIO, INC (ANAB)
- Ticker
- ANAB
- Market Cap
- $1.5B
- Latest Price
- $50.87
- Industry
- Biotech & Pharma
ANAPTYSBIO, INC (ANAB) Top Institutional Holders
Top current 13F holders indexed for ANAPTYSBIO, INC (ANAB). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Ken FisherCIK 0000850529 | $3.1M | 0.0% | Filing2026-05-05 |
| 2 | Joel GreenblattCIK 0001510387 | $774,887 | 0.0% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.